InMed Pharmaceuticals logo

InMed Pharmaceuticals

Global leader in the manufacturing and development of rare cannabinoids. Our subsidiary is Baymedica. Nasdaq: $INM

18 employees · est. 1981 · Canada

VS
Nalu Bio  logo

Nalu Bio

Harnessing the power of the endocannabinoid system for a healthier future

17 employees · est. 2019 · San Francisco, United States

InMed Pharmaceuticals is the older company (1981 vs 2019).

Side-by-Side Comparison

InMed Pharmaceuticals Nalu Bio
Founded
1981 older 2019
Headquarters
Canada San Francisco, United States
Employees
18 17
Industry
Biotechnology, Health Care, Pharmaceutical Biotechnology, Health Care
Funding Stage
Post Ipo Equity Series A
Total Funding
Not tracked yet $12.25M
Funding Rounds
13 4
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Pharmaceuticals, Drug Development, Cannabinoids, Rare Cannabinoids, Therapeutic Medications, Alzheimer's Treatment, Ocular Indications, Dermatological Indications, Small Molecule Drugs, Clinical-stage Pharmaceuticals, CB1/CB2 Receptors, Medical Research Biotech Company, Cannabinoids, Health And Wellness, Predictive AI Modeling, Chemistry-derived Cannabinoids, Therapeutics, Minor Cannabinoids, CPG Industry, NCEs, Health Tech, San Francisco, Female-founded, Data-driven, Personal Care
Website
inmedpharma.com nalubio.com
InMed Pharmaceuticals logo

About InMed Pharmaceuticals

InMed Pharmaceuticals, founded in 1981, is a biotechnology company headquartered in Canada. The company is recognized as a global leader in the manufacturing and development of rare cannabinoids, strategically aligning with its subsidiary, BayMedica. With a focus on developing proprietary small mol...

Nalu Bio  logo

About Nalu Bio

Nalu Bio is a San Francisco-based biotech startup, with a mission to unlock the potential of cannabinoids for the betterment of humanity and the planet. Founded in 2019, the company is helmed by a female-led team. Nalu Bio leverages innovative chemistry and predictive AI modeling to address prevalen...

We will tell you when either one moves

BounceWatch watches InMed Pharmaceuticals and Nalu Bio for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at InMed Pharmaceuticals and Nalu Bio — by email.

Frequently Asked Questions

InMed Pharmaceuticals — Global leader in the manufacturing and development of rare cannabinoids. Our subsidiary is Baymedica. Nasdaq: $INM. Nalu Bio — Harnessing the power of the endocannabinoid system for a healthier future. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
InMed Pharmaceuticals has raised undisclosed funding while Nalu Bio has raised $12.25M.
InMed Pharmaceuticals and Nalu Bio operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare InMed Pharmaceuticals with someone else

Start typing a company name or domain.

Related Comparisons

Compiled from the BounceWatch company index. We last looked at InMed Pharmaceuticals on 15 Nov 2024, and Nalu Bio on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes